MIAMI, FL / ACCESS Newswire / November 4, 2025 / NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies, today announced that it will be presenting its strategic development plans to establish a global decentralized supply chain and clinical development initiation for its ²¹¹At targeted alpha therapy pipeline at the Network for Optimized Astatine-Labeled Radiopharmaceuticals (NOAR) Europe annual meeting in Nantes, France.

"NAYA is committed to leading the implementation of a global decentralized GMP manufacturing network to unlock the potential of our ²¹¹At clinical pipeline," commented Dr. Daniel Teper, NAYA's CEO. "We believe that astatine-211's unique properties are ideally-suited to address the needs of patients at risk of residual disease & micrometastasis in hepatocellular carcinoma (HCC) and multiple myeloma, our two lead indications."

"We're delighted to welcome NAYA Therapeutics as a pioneering biopharmaceutical company focused on the development of astatine-211 radiopharmaceuticals," commented Dr. Jean-François Gestin, Co-Chair of NOAR Europe. "2026 will be a key inflection year for the translation of over 20 years of ²¹¹At academic research towards the clinical development & commercialization of a new generation of targeted alpha therapies. A rapidly-growing number of experts believe that ²¹¹At radiopharmaceuticals have the potential to become the safest, cleanest, and most effective alpha therapies as they become widely available."

About NAYA

NAYA Therapeutics is pioneering the next generation of cancer therapies, aiming to unlock deeper, more durable responses in patients not responding to current standard-of-care. NAYA's pipeline harnesses the transformational potential of two synergistic modalities: Astatine-211 (²¹¹At) targeted alpha therapies & NK cell engaging bifunctional antibodies, with an initial focus on hepatocellular carcinoma (HCC). For more information, please visit www.nayatx.com.

About NOAR

NOAR COST Action brings together European and international excellence labs, astatine-211 production centers, hospitals, industry and patient associations from more than 20 countries, thus covering the whole value chain of innovation: production, chemistry, radiochemistry, biology, preclinical and clinical research and delivery of radiopharmaceuticals to patients.

NAYA Media & Investor Contact

Lyn Falconio, Chief Communications Officer
917-575-1844
lyn@nayatx.com

NOAR Media Contact

Jean-François Gestin, Co-Chair
jean-francois.gestin@univ-nantes.fr

SOURCE: NAYA Therapeutics